Cargando…
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care
BACKGROUND: For advanced non-small cell lung cancer anti-PD-1 treatment has become standard care in first and second line treatment in recent years. Because many of the clinical trials with anti-PD-1 drugs have only recently been completed, long term follow up data of patients treated with these age...
Autores principales: | Schouten, Robert D., Egberink, Lucie, Muller, Mirte, De Gooijer, Cornedine J., van Werkhoven, Erik, van den Heuvel, Michel M., Baas, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653122/ https://www.ncbi.nlm.nih.gov/pubmed/33209597 http://dx.doi.org/10.21037/tlcr-19-698 |
Ejemplares similares
-
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020) -
New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago, Giulia, et al.
Publicado: (2016) -
Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020) -
Routine vaccination for influenza and pneumococcal disease and its effect on COVID-19 in a population of Dutch older adults
por: Taks, Esther J.M., et al.
Publicado: (2023) -
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)